Exploring the Therapeutic Potential of Scenic Biotech's PLA2G15 Inhibitor Program in Parkinson's Disease: A Collaboration with MJFF LITE Program
Scenic Biotech, a company specializing in neurometabolic research, has partnered with The Michael J. Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. This collaboration aims to explore the therapeutic potential of Scenic's PLA2G15 inhibitor program in Parkinson's disease, particularly in patients with LRRK2 mutations. The focus will be on restoring lysosomal function, a key factor in neurodegeneration.
The Senior Vice President of Discovery and Translational Research at MJFF, Shalini Padmanabhan, highlighted the importance of accelerating the evaluation of therapeutic strategies related to LRRK2 biology. Scenic's unique approach to lysosomal health and lipid metabolism aligns well with the goals of the LITE program, which aims to strengthen the connection between lysosomal biology and Parkinson's disease.
Scenic Biotech's Chief Scientific Officer, Roland Bűrli, emphasized the significance of expanding the application of PLA2G15 inhibitors beyond rare diseases. With increasing evidence linking lysosomal dysfunction to Parkinson's disease, the collaboration with LITE will leverage expertise in LRRK2 biology, biomarker infrastructure, and academic models to assess the potential benefits of improving lysosomal function for patients.
The initial phase of the collaboration will involve testing PLA2G15 inhibitors in established preclinical models developed at the University of Dundee. The goal is to generate data that can support and expedite future clinical development efforts. The Director of the MRC Protein Phosphorylation Unit at the University of Dundee, Dario Alessi, expressed enthusiasm about integrating Scenic's inhibitors into the LITE framework to explore the intersection of lysosomal biology and LRRK2-linked Parkinson's disease. This partnership will leverage Dundee's expertise in models, tools, and biomarkers to advance the translational potential of this therapeutic approach.
In conclusion, the collaboration between Scenic Biotech and the MJFF LITE program represents a significant step towards advancing research on Parkinson's disease. By combining expertise in lysosomal function and LRRK2 biology, the partnership aims to develop innovative therapies that could benefit patients with Parkinson's disease, particularly those with LRRK2 mutations.